Cantor Fitzgerald Starts Avalo Therapeutics Inc. (AVTX) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts AVTX Hot Sheet
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Overweight rating.
The analyst comments "We are initiating coverage of Avalo Therapeutics (AVTX) with an Overweight rating. Avalo is a clinical-stage biotech focused on autoimmune diseases. Its lead drug, AVTX-009, is an IL-1β antibody currently in a Phase 2 trial for Hidradenitis Suppurativa (HS) – a severe skin disease. Ph2 HS trial is guided to read out in mid-2026."
For an analyst ratings summary and ratings history on Avalo Therapeutics Inc. click here. For more ratings news on Avalo Therapeutics Inc. click here.
Shares of Avalo Therapeutics Inc. closed at $8.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
- Bayfirst Financial Corp (BAFN) Tops Q3 EPS by 4c
- Gouverneur Bancorp, Inc. (GOVB) Tops Q4 EPS by 23c
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Cantor Fitzgerald, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
